Investors who purchased Kyndryl Holdings (NYSE: KD) stock between August 1, 2024, and February 9, 2026, have until April 13, 2026, to file an application to serve as lead plaintiff in a class action lawsuit alleging that company executives manipulated financial metrics and misled shareholders. After that date, investors can remain in the lawsuit as absent class members but will lose the opportunity to direct the case or significantly influence its strategy and settlement terms. This deadline applies specifically to the case *Brander v. Kyndryl Holdings, Inc., et al* (Case No.
1:26-cv-00782, E.D.N.Y.), one of several lawsuits stemming from the company’s financial disclosures and dramatic stock declines. The lawsuit centers on allegations that Kyndryl executives artificially inflated free cash flow metrics through vendor payment deferrals, failed to disclose material weaknesses in internal controls, and provided financial statements that did not accurately reflect the company’s true operational performance. The case gained momentum after two major stock crashes: a 21.1% drop on August 4, 2025, when the company missed revenue and free cash flow estimates, and a catastrophic 54% decline on February 9, 2026—dropping from $23.49 to $10.59 per share—following the departures of the company’s CFO and General Counsel and an SEC request for documents on cash management practices. Understanding your rights in this case requires knowing the difference between serving as a lead plaintiff and remaining as a class member, the specific allegations driving the lawsuit, and what the April 13 deadline actually means for your potential recovery.
Table of Contents
- What Does the April 13, 2026 Deadline Mean for Kyndryl Investors?
- Understanding the Allegations Against Kyndryl Executives
- The Two Stock Price Collapses That Triggered the Lawsuit
- Who Qualifies as a Class Member and What Are Your Options?
- Understanding Absent Class Member Status and Recovery Limitations
- The Legal Teams Handling Kyndryl Cases and Their Experience
- What to Expect in the Coming Months and Years
What Does the April 13, 2026 Deadline Mean for Kyndryl Investors?
The April 13, 2026 deadline is a court-imposed cutoff for investors interested in serving as the lead plaintiff—the named representative who acts on behalf of the entire class. Lead plaintiffs do not receive special recoveries but they do control important decisions about the case, including approving settlement amounts and attorneys’ fees. After April 13, you can still be part of the lawsuit, but only as a passive member with no say in how the case proceeds. For example, if the lead plaintiff negotiates a settlement you believe is too low, or if they approve attorneys’ fees you find unreasonable, you would have no formal recourse once the deadline passes.
Filing to be lead plaintiff requires submitting documentation to the court proving your Kyndryl stock ownership during the class period (August 1, 2024 through February 9, 2026) and demonstrating that you have a “material interest” in the case. The lead plaintiff position typically goes to the investor with the largest financial loss, though courts can appoint multiple lead plaintiffs if circumstances warrant. Even if you don’t meet the qualifications for lead plaintiff status, submitting the necessary documentation before April 13 ensures you remain eligible to recover any settlement proceeds eventually awarded to the class.
Understanding the Allegations Against Kyndryl Executives
The core allegations in the Brander lawsuit involve a practice known as vendor payment manipulation—Kyndryl executives allegedly deferred payments to vendors between quarters to artificially inflate free cash flow figures reported to investors. Free cash flow is a critical metric that investors use to assess whether a company generates real cash from operations rather than just reporting accounting profits, making it a key factor in stock valuations. When a company defers paying vendors, cash stays on the balance sheet temporarily, creating an appearance of stronger financial health than actually exists. Once deferred payments come due, the metric reverses, often dramatically.
However, vendor payment timing is a detailed area where normal business management can appear suspicious. The lawsuit specifically alleges that Kyndryl’s deferrals were not routine working capital management but rather intentional manipulation designed to mislead investors about operational performance. The case also includes allegations that Kyndryl failed to disclose material weaknesses in internal controls over financial reporting, meaning the company allegedly knew or should have known that its financial monitoring systems had gaps. When a company omits such disclosures, investors cannot adjust their assessments of financial reliability, making the fraudulent statements more damaging.
The Two Stock Price Collapses That Triggered the Lawsuit
The first major stock decline occurred on August 4, 2025, when Kyndryl stock fell $7.76 per share—a 21.1% single-day drop—after the company missed both revenue and free cash flow guidance. This announcement signaled that the company’s operational performance was worse than previously disclosed, immediately raising questions about the accuracy of earlier financial statements. Investors who had relied on management’s representations when making purchase decisions above this new price point suffered direct losses.
The second and more dramatic collapse happened on February 9, 2026, when the stock plummeted 54% in a single trading session, sliding from $23.49 to $10.59 per share. This decline was precipitated by two simultaneous events: the departures of both the Chief Financial Officer and General Counsel, and an SEC request for the company to voluntarily provide documents regarding its cash management practices. The dual departures of the top financial and legal executives signaled to the market that serious issues had surfaced, and the SEC inquiry suggested potential investigation into the very cash management practices at the heart of the class action allegations. For investors who had purchased Kyndryl stock during the August 1, 2024 to February 9, 2026 class period, these two collapses meant significant paper losses.
Who Qualifies as a Class Member and What Are Your Options?
You qualify for this Kyndryl class action if you purchased Kyndryl Holdings stock (common stock traded under ticker NYSE: KD) at any point between August 1, 2024, and February 9, 2026, and held the shares for some period of time. The class definition does not exclude people who sold at a profit, though your recoverable damages calculation depends on when you bought and sold relative to the major stock declines.
If you bought at $20 per share in December 2024 and sold at $15 per share in January 2026, your loss is $5 per share; if you held until the February 9 collapse, your loss would be much larger. Once you determine you are part of the class, you have three practical options: (1) Do nothing and wait—you will automatically be included as an absent class member if a settlement is reached, and the court will attempt to notify you about claiming procedures; (2) File to become lead plaintiff by April 13, 2026, if you meet the eligibility criteria and have the interest and time to oversee the case; or (3) Consult with one of the lead law firms handling the matter to understand your specific situation before deciding. The trade-off is that doing nothing carries the risk that you might miss a settlement notice or claim deadline years from now, while filing for lead plaintiff status requires active participation now.
Understanding Absent Class Member Status and Recovery Limitations
If you remain as an absent class member after April 13, 2026, you will still have the right to share in any settlement or judgment that the class wins, but only if you file a valid claim when the case concludes. This claim filing process typically occurs years after the original lawsuit is filed, once settlement negotiations are finalized and approved by the court. The notice and claim procedures will be mailed to your last known address based on stock brokerage records, but if you have moved or your records are outdated, you might not receive notification—and missing the claim deadline forfeits your recovery entirely.
A significant limitation applies to absent class members: you typically lose the right to object to the settlement amount or the attorneys’ fees being awarded to the plaintiff’s lawyers, which can range from 25% to 33% of any recovery. Lead plaintiffs can negotiate these terms, but passive members accept whatever lead counsel negotiates. Additionally, if the case drags on for five to seven years (not uncommon for securities class actions), the value of any recovery may be further reduced by inflation and by the time value of money. If you purchased 500 shares at an average price of $22 and the class recovers $3 per share, your gross recovery is $1,500 before attorneys’ fees—a material amount for many investors but far less than the original loss.
The Legal Teams Handling Kyndryl Cases and Their Experience
Multiple law firms are actively pursuing Kyndryl claims, including Kessler Topaz Meltzer & Check, LLP; Kahn Swick & Foti, LLC; and Faruqi & Faruqi, LLP. These firms have significant experience handling securities class actions involving financial fraud allegations, and their track records include numerous settlements worth millions of dollars. For example, Kessler Topaz has recovered more than $3 billion for investors in past cases, while Faruqi & Faruqi has recovered over $1.1 billion.
Having multiple law firms investigating the same facts can sometimes lead to a consolidated case or coordinated discovery, which can strengthen the overall claim. If you are considering becoming lead plaintiff or want to better understand the details of the allegations, contacting one of these firms is a logical first step. They typically work on a contingency basis, meaning they collect their fees from any settlement, and they have no cost to investors for initial consultations. However, remember that the lead plaintiff position does not mean hiring private counsel to represent you separately—the court-appointed lead counsel will represent the entire class in the consolidated litigation.
What to Expect in the Coming Months and Years
After the April 13, 2026 lead plaintiff deadline, the case will move through discovery, where both sides exchange documents and take depositions. At Kyndryl’s size and complexity, discovery can easily last 18 to 24 months or more. During this phase, the plaintiff’s lawyers will seek evidence of how management made decisions about vendor payments, what disclosures were prepared, and what the company knew about its internal control weaknesses. Kyndryl’s counsel will defend against the allegations, arguing either that practices were routine or that any misstatements did not cause the stock declines.
Settlement discussions often begin mid-litigation and can take several years to resolve. Unlike a criminal case, settlements in securities class actions frequently result in payouts of 10% to 30% of the total estimated damages claimed, rather than 100% recovery. The final settlement amount depends on many factors: the strength of the evidence, the defendants’ appetite for risk in litigation, and the insurer’s coverage limits. Investors should not expect a settlement announcement imminently; April 13 is a procedural milestone, not a settlement trigger.